Cogent Biosciences (COGT) Total Current Liabilities (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Total Current Liabilities data on file, last reported at $58.0 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 17.57% year-over-year to $58.0 million in Q1 2026; TTM through Mar 2026 was $58.0 million, a 17.57% increase from a year earlier, with the FY2025 full-year figure at $64.0 million, up 14.8% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $58.0 million, down from $64.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for COGT reached as high as $64.0 million in Q4 2025 and fell as low as $17.9 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $40.8 million across 5 years, with a median of $38.2 million in 2023.
• Across the five-year window, Total Current Liabilities soared 116.93% in 2022 and slipped 6.87% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $26.8 million in 2022, then jumped by 42.16% to $38.2 million in 2023, then soared by 45.96% to $55.7 million in 2024, then increased by 14.8% to $64.0 million in 2025, then declined by 9.34% to $58.0 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $58.0 million in Q1 2026, $64.0 million in Q4 2025, and $62.2 million in Q3 2025.